Transport, pharma and biotech as industry become India’s biggest research investors
The report also shows that industry now employs more researchers than the public sector in core R&D activities, underscoring a broader shift in the country’s innovation landscape.
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
The (DST) released its Research and Development Statistics 2025-26 report, highlighting a significant structural shift in India's innovation ecosystem. For the first time, private industry research spending has surpassed combined government spending, driven primarily by the transportation, pharmaceutical, biotechnology, and IT sectors. Furthermore, India’s overall R&D expenditure crossed the 0.8% of GDP mark in 2021-22 and is projected to near 0.9% by 2025-26, signaling a maturing, industry-led research landscape.
UPSC Perspectives
Economic
This shift represents a maturation of the Indian economy, moving from a low-cost manufacturing or service-delivery model to a knowledge-based economy. Historically, India's R&D expenditure hovered around 0.7% of GDP, significantly lower than global leaders like the US (over 3%) or China (over 2%), and was predominantly funded by the government through institutions like and . The data showing private industry accounting for 51.8% of national R&D spending in 2023-24 aligns India's innovation model more closely with developed economies, where the private sector typically drives commercial research. The 'post-COVID' realization among corporates that R&D is critical for survival and competitiveness has catalyzed this investment. Furthermore, stricter norms on disclosing R&D spending have likely improved data capture. For UPSC, this highlights the growing role of the private sector in achieving self-reliance and the transition towards high-value economic activities.
Science and Technology
The sector-specific breakdown provides critical insights into India's technological trajectory. The transportation sector's emergence as the largest R&D spender reflects the massive transition towards electric vehicles (EVs), alternative fuels, and advanced automotive technologies. The high research intensity (R&D spend as a percentage of sales turnover) in biotechnology (16.8%) and pharmaceuticals underscores India's strategic push in healthcare innovation, moving beyond generic drug manufacturing towards novel drug discovery and biomanufacturing. The fact that the private sector now employs more full-time equivalent (FTE) R&D personnel than the government signifies a shift in the primary locus of innovation. This raises important policy questions about how the government can further incentivize this trend, perhaps through expanded tax credits or stronger industry-academia linkages to bridge the gap between basic research (usually government-funded) and applied, commercial research (industry-funded).
Governance
The changing R&D landscape demands a recalibration of government policy regarding innovation. While the private sector leads in applied research and commercialization, the state's role remains crucial in funding basic science (fundamental research with no immediate commercial application) and supporting research in areas with low private interest but high social value, such as neglected tropical diseases or public health infrastructure. The government's introduction of the (ANRF) bill aims to seed, grow, and promote R&D and foster a culture of research and innovation across universities, colleges, and research institutions. The challenge for policymakers will be to create synergies between the expanding private R&D ecosystem and public research institutions, ensuring that intellectual property generated benefits the broader national interest. UPSC aspirants should analyze whether current policies effectively encourage this collaboration or if structural bottlenecks persist.